Spatial Biology – News and Features

University of Michigan researchers identified UBA1 as a key player in immunotherapy resistance. Inhibiting UBA1 boosts T-cell recruitment, converting cold tumors to hot, and enhancing the effectiveness of immune checkpoint blockade therapies.

Researchers discovered that starlet sea anemones reshape their entire bodies during regeneration to maintain their original proportions. Using spatial transcriptomics, the team identified enzymes active throughout the body that realign tissues.

Researchers discovered that tumors grow uniformly throughout their mass, challenging the idea of faster growth at edges. Spatial genomics and simulations revealed evenly distributed mutations within tumors.

NYU Langone researchers found cancer cells resist chemotherapy in low-glucose environments by conserving pyrimidines and blocking apoptosis pathways. These adaptations minimize drug effectiveness by altering metabolism.

Researchers discovered that tumors grow uniformly throughout their mass, rather than faster at the edges. Using spatial genomics and computer simulations, the study analyzed mutation patterns in liver cancer.

Researchers mapped gene expression across the mouse intestine, revealing its stability and adaptability to changes like inflammation. The study identified immune-controlled regions and resilient spatial patterns.

A thymus atlas reveals that immune foundations are set as early as 12 weeks post-conception. Researchers uncovered key T cell development processes, offering insights for engineering immune cells to treat cancer and autoimmune diseases.

A study reveals that 3% of normal breast cells in healthy women have chromosomal abnormalities linked to invasive breast cancer, challenging current cancer detection methods. Aneuploid cells accumulate with age and mimic invasive cancer profiles.

New research provides insights into the diversity of cancer-associated fibroblasts in white and black skin cancer and describes their different immunomodulatory roles in the tumor environment.

A novel CAR-T therapy targeting p95HER2 shows complete and durable tumor responses in HER2+ breast cancer preclinical models. Combining CAR-T cells with a bispecific antibody, this approach enhances immune activation while avoiding toxicities.